Neoadjuvant trastuzumab deruxtecan shows clinical activity in patients with HER2-low breast cancer

Professional, doctor. Scientist with microscope

Patients with localized, hormone receptor-positive, HER2-low breast cancer treated with trastuzumab deruxtecan (T-DXd, Enhertu) in the neoadjuvant setting had an overall response rate of 75 percent in the absence of anastrozole and 63 percent in combination with anastrozole, according to results from the phase II TRIO-US B-12 TALENT trial presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

T-DXd yields superior outcomes over chemotherapy-based regimens in patients previously treated with T-DM1

Previous article

Q and A: Teen stretch marks

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations